A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US^*

References

• Kahn S. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3-19
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006;29:S43-8
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States. Atlanta, GA, USA, 2007
   Google Scholar
• Roper N, Bilous R, Kelly W, et al. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ 2001;322:1389-93
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-6
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes (UKPDS 40). BMJ 1998;317:720-6
   PubMed Web of Science ®Google Scholar
• Clarke P, Gray A, Briggs A, et al. Cost-utility analysis of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005;48:868-77
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93
   PubMed Web of Science ®Google Scholar
• Jacobs M, Kleisli T, Pio J, et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract 2005;70:263-9
   PubMed Web of Science ®Google Scholar
• Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero A, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004;26:744-54
   PubMed Web of Science ®Google Scholar
• Czoski-Murray C, Warren E, Chilcott J, et al. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technol Assess 2004;13:1-91
   Google Scholar
• Tilden DP, Mariz S, O’Bryan-Tear G, et al. A lifetime modeled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics 2007;25:39-54
   PubMed Web of Science ®Google Scholar
• Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, et al. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand. Value Health 2008;11(Suppl 1):S43-51
   PubMedGoogle Scholar
• Tunis SL, Minshall ME, St. Charles M, et al. Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. Curr Med Res Opin 2008;24:3085-96
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of pioglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• Moon KT. Rosiglitazone is associated with increased cardiovascular mortality (Editor's note). Am Family Physician 2008;77: available on line http://www.aafp.org/afp/. Last accessed December 2 2008).
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2008. Diabetes Care 2008;31:S12-54
   PubMed Web of Science ®Google Scholar
• Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-40
   PubMed Web of Science ®Google Scholar
• Riddle MC. Is initial combination therapy effective in the treatment of type 2 diabetes? Nature Clin Prac Endocrinology Metab 2006;2:254-5
   PubMed Web of Science ®Google Scholar
• Derosa G, D'Angelo A, Ragonesi PD, et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetes patients with metabolic syndrome. J Clin Pharm Ther 2006;31:375-83
   PubMed Web of Science ®Google Scholar
• Bell D, Wyne K. Treatment of type 2 diabetes: use of fixed-dose oral combinations. Postgrad Med 2006;119:8-14
   PubMedGoogle Scholar
• Grundy S. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2005;47:1093-100
   Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin 2004;20:S5-26
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004;20:S27-40
   PubMed Web of Science ®Google Scholar
• NHANES 1999--2000 Dataset: Diabetes Survey. National Center for Health Statistics, Centers for Disease Control and Prevention. NHANES, 2002
   Google Scholar
• Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2-9
   PubMed Web of Science ®Google Scholar
• Phillips SJ, Whisnant JP, O'Fallon WM, et al. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc 1990;65:344-59
   PubMed Web of Science ®Google Scholar
• Miller CD, Phillips LS, Tate MK, et al. Meeting American Diabetes Association guidelines in endocrinologist practice. Diabetes Care 2000;23:444-8
   PubMed Web of Science ®Google Scholar
• Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000;23:754-8
   PubMed Web of Science ®Google Scholar
• Harris MI, Cowie CC, Stern MP. Diabetes in America, 2nd edn. (NIH publication no. 95-1468). Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, 1995
   Google Scholar
• Brändle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300-4
   PubMed Web of Science ®Google Scholar
• Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 1992;152:610-6
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996
   Google Scholar
• O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003;25:1017-38
   PubMed Web of Science ®Google Scholar
• DRG Guidebook. A Comprehensive Resource to the DRG Classification System. St. Anthony Publishing, 2001
   Google Scholar
• Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S. Diabetes Care 2003;26:2305-10
   PubMed Web of Science ®Google Scholar
• Bullano MF, Al-Zakwani IS, Fisher MD, et al. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin 2005;21:291-8
   PubMed Web of Science ®Google Scholar
• Drug Topics Red Book. Montvale, NJ, Medical Economics Company, 2004
   Google Scholar
• Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999;131:660-7
   PubMed Web of Science ®Google Scholar
• O'Brien J, Shompe L, Kavanagh P, et al. Direct medical costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 1998;21:1122-8
   PubMed Web of Science ®Google Scholar
• Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: A cost-effectiveness analysis. Dermatol Surg 2001;27:347-51
   PubMed Web of Science ®Google Scholar
• US Department of Labor, Bureau of Labor Statistics, Consumer Price Index for the Healthcare Sector, 2006. Washington DC: Division of Consumer Prices and Price Indexes, 2006
   Google Scholar
• American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-5
   Google Scholar
• Tarn T, Smith M. Pharmacoeconomics guidelines around the world. ISPOR Connections 2004;10:5-15
   Google Scholar
• Halpern EF, Weinstein MC, Hunink MG, et al. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Dec Making 2000;20:314-22
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationEconomic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:1-20
   Web of Science ®Google Scholar